Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 13 and set a price target of ...

Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years.

At Holdings Channel, we have reviewed the latest batch of the 42 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Novartis (Symbol: NVS) was held by 16 of these funds.

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal said on ...